A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
Recommended Citation
Singh H, Ahmed O, Allen E, and Othman H. A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion. J Investig Med High Impact Case Rep 2023; 11:23247096231209554.
Document Type
Article
Publication Date
11-2-2023
Publication Title
J Investig Med High Impact Case Rep
Abstract
Stress cardiomyopathy is a transient left ventricular dysfunction caused by physiologic or pathologic stressors. Anaphylaxis is a hypersensitivity disorder that can lead to a rapid life-threatening respiratory collapse. It happens due to exposure to allergens including medications. During anaphylaxis, there is a compensatory release of catecholamines that can lead to stress cardiomyopathy. In this case, nab-paclitaxel infusion led to anaphylaxis with respiratory failure. Echocardiogram showed features of diffuse hypokinesis with preserved basal segment contractility, and cardiac catheterization did not show any evidence of obstructive coronary artery disease. The overall clinical picture suggested stress cardiomyopathy. The patient was treated with guideline-directed medical therapy which resulted in normalization of the ejection fraction with no symptoms of congestive heart failure at any point. The patient was thereafter resumed on a reduced dose of nab-paclitaxel. This case report adds to the spectrum of infusion-related reactions associated with paclitaxel and demonstrates the course of events in the management of anaphylaxis and stress cardiomyopathy in this scenario.
Medical Subject Headings
Humans; Anaphylaxis; Echocardiography; Paclitaxel; Takotsubo Cardiomyopathy
PubMed ID
37919938
Volume
11
First Page
23247096231209554
Last Page
23247096231209554